Molina-Par?s C., Lythe G. (editors) Mathematical Models and Immune Cell Biology
Подождите немного. Документ загружается.
19 Viral Immunity and Persistence 403
102. Beck S, Barrell BG (1988) Human cytomegalovirus encodes a glycoprotein homologous to
MHC class-i antigens. Nature 331:269–272
103. Browne H, Smith G, Beck S, Minson T (1990) A complex between the MHC class I homo-
logue encoded by human cytomegalovirus and ˇ 2 microglobulin. Nature 347:770–772
104. Fahnestock ML, Johnson JL, Feldman RM, Neveu JM, Lane WS, Bjorkman PJ (1995)
The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides.
Immunity 3:583–590
105. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL (1997)
The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells.
Nature 386:514–517
106. Shisler J, Yang C, Walter B, Ware CF, Gooding LR (1997) The adenovirus E3-10.4K/14.5K
complex mediates loss of cell surface fas (CD95) and resistance to fas-induced apoptosis.
J Virol 71:8299–8306
107. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K,
Wells CE, Doherty PC, Wold WS (1998) Forced degradation of fas inhibits apoptosis in
adenovirus-infected cells. Nature 392:726–730
108. Barker DD, Berk AJ (1987) Adenovirus proteins from both e1b reading frames are required
for transformation of rodent cells by viral infection and dna transfection. Virology 156:
107–121
109. Kao CC, Yew PR, Berk AJ (1990) Domains required for in vitro association between the
cellular p53 and the adenovirus 2 e1b 55k proteins. Virology 179:806–814
110. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 onco-
protein is able to bind to the retinoblastoma gene product. Science 243:934–937
111. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M,
Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor
signals by cellular flip. Nature 388:190–195
112. Komiyama T, Quan LT, Salvesen GS (1996) Inhibition of cysteine and serine proteinases by
the cowpox virus serpin CRMA. Adv Exp Med Biol 389:173–176
113. Tewari M, Telford WG, Miller RA, Dixit VM (1995) Crma, a poxvirus-encoded serpin, in-
hibits cytotoxic T-lymphocyte-mediated apoptosis. J Biol Chem 270:22705–22708
114. Zhou Q, Salvesen GS (2000) Viral caspase inhibitors CrmA and p35. Methods Enzymol
322:143–154
115. Elena SF, Sanjuan R (2005) Adaptive value of high mutation rates of RNA viruses: separating
causes from consequences. J Virol 79:11555–11558
116. Jenkins GM, Rambaut A, Pybus OG, Holmes EC (2002) Rates of molecular evolution in rna
viruses: a quantitative phylogenetic analysis. J Mol Evol 54:156–165
117. Drake JW, Charlesworth B, Charlesworth D, Crow JF (1998) Rates of spontaneous mutation.
Genetics 148:1667–1686
118. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn
BH, Oldstone MB, Shaw GM (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic
T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL es-
cape virus. Nat Med 3:205–211
119. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG,
Rothbard JA, Bangham CR, Rizza CR, et al (1991) Human immunodeficiency virus genetic
variation that can escape cytotoxic T cell recognition. Nature 354:453–459
120. Beekman NJ, van Veelen PA, van Hall T, Neisig A, Sijts A, Camps M, Kloetzel PM,
Neefjes JJ, Melief CJ, Ossendorp F (2000) Abrogation of CTL epitope processing by sin-
gle amino acid substitution flanking the c-terminal proteasome cleavage site. J Immunol 164:
1898–1905
121. Zimbwa P, Milicic A, Frater J, Scriba TJ, Willis A, Goulder PJ, Pillay T, Gunthard H,
Weber JN, Zhang HT, Phillips RE (2007) Precise identification of a human immunodeficiency
virus type 1 antigen processing mutant. J Virol 81:2031–2038
122. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, Walker BD,
Goulder PJ (2004) Immune escape precedes breakthrough human immunodeficiency virus
404 S. Hickling and R. Phillips
type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-
positive long-term-nonprogressing child. J Virol 78:8927–8930
123. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, Workman C, Shaunak S,
Olson K, Goulder P, Brander C, Ogg G, Sullivan JS, Dyer W, Jones I, McMichael AJ,
Rowland-Jones S, Phillips RE (2001) Clustered mutations in HIV-1 gag are consistently re-
quired for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med
193:375–386
124. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CR,
Phillips RE (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during
primary infection. Proc Natl Acad Sci USA 94:1890–1895
125. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P,
Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S (1997) Late escape from
an immunodominant cytotoxic t-lymphocyte response associated with progression to aids.
Nat Med 3:212–217
126. Asquith B, McLean AR (2007) In vivo CD8
C
T cell control of immunodeficiency virus in-
fection in humans and macaques. Proc Natl Acad Sci USA 104:6365–6370
127. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C,
Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C,
Walker BD, Stuart DI, Kiepiela P, Goulder P (2006) Fitness cost of escape mutations in
p24 gag in association with control of human immunodeficiency virus type 1. J Virol 80:
3617–3623
Index
Symbols
2
, 247
A
absorbing state, 175, 195
adaptive immune system, 259
affinity maturation, 121, 132, 242
agent-based model, 129, 135
Aire, 17–19
APC, 14, 49, 79, 171, 188, 233, 277, 281, 351
APP, 172, 188
assumptions, 243, 247
B
B cell, 108, 121, 260
migration, 128, 132, 135
autoreactive, 262
development, 262
dynamics, 262
transfers, 261
birth and death process, 174
bone marrow survival niches, 263
bootstrap method, 161
branching process, 115, 117
BrdU labelling, 150
Brownian motion, 352
C
cell cycle, 308
cell division, 108, 147
cell shape dynamics, 135
cell track models, 125
cell tracking, 125
cellular activation threshold, 49
centroblasts, 242
centrocytes, 242
CFSE, 108
chemokine, 6, 10, 19
chemotaxis, 132, 343
chimeras, 246
clonotype, 207
co-receptor, 50
CD4, 50
CD8, 50
kinetics, 53
conformational change models, 35
cortex, 3, 6, 19
costimulation, 82, 95
CD152, 59
CD28, 59
CD80, 59
CD86, 59
signal 2, 58
crossregulation model, 277, 307
cyton, 110
cytotoxic T lymphocytes, 363, 391
D
decay parameter, 220
dendritic cell, 19, 76, 131, 227, 342, 359
follicular, 242
migration, 228
E
endoplasmic reticulum, 388
epithelium, 2–6, 13–15, 17–19
escape mutant, 365
extinction, 172, 195, 201, 204
F
feedback control of signalling, 33
finite state projection, 207
C. Molina-Par´ıs and G. Lythe (eds.), Mathematical Models and Immune Cell Biology, 405
DOI 10.1007/978-1-4419-7725-0,
c
Springer Science+Business Media, LLC 2011
406 Index
fluctuation-dissipation, 343
follicles, 242
functional sensitivity, 48
G
gastrointestinal tract, 228
germinal centre, 121, 128, 132, 242, 263
morphology, 128, 132
reaction, 128, 132
diversity, 251
mixed, 248
sections, 247
single, 248
H
HIV, 142, 363, 365, 378, 393, 395, 396
HLA, 384
homeostasis, 147, 208
hypotheses, 244
I
IL-2, 79, 90, 92, 260, 305, 306, 328, 331
IL-7, 4, 94, 260, 320
IL-15, 96, 260, 309
immunological synapse, 80
innate immune response, 384
innate-like lymphocytes, 266
interactions between cells, 123, 129, 137, 359
interpretations, 244
intravital microscopy, 123, 135, 137
K
Ki67, 143, 144
kinetic proofreading, 28
kinetic segregation model, 39
Krylov subspace, 207
L
Laplace’s equation, 354
ligand, 32, 82, 91, 346
limiting conditional distribution, 176
lymph node, 112, 131, 171, 231, 235, 255, 268,
308, 311, 315, 323, 325, 345, 351
M
Magnus expansion, 207
Markov process, 172, 188, 207
master equation, 207
maximum likelihood, 158
mean path length of cells, 123
medulla, 6, 9, 13, 17–19
memory B cells, 242, 263
memory T cells, 93, 143, 148, 149
Merck vaccine, 364, 376
MHC, 4, 12, 26, 39, 41, 48, 49, 76, 171, 246,
348, 384
migration of cells, 121, 123, 137
molecular aggregation models, 36
motility, 123, 342
multi-photon microscopy, 123, 135, 137
N
natural killer cells, 228, 384
negative selection, 89
negative selection, 20
negative selection, 12, 16, 19, 86, 132, 262
null peptide, 48
O
oligoclonal, 242
order of magnitude, 346
P
pattern recognition receptors, 230
Poisson equation, 358
positive selection, 9, 13, 14, 270
Potts model, 131
Q
quasi-stationary distribution, 214
R
reaction-diffusion system, 132
rebinding, 31
recycling, 243
S
scales, 340
seeding, 242
shape space concept, 132
SHIV, 376
SHM, 242
signal integration, 131
signalling through differential affinity, 59
Index 407
software, 159
somatic hypermutation, 242
speed of cells, 123
stable-isotope labelling, 151
STEP Study, 364
Stochastic Simulation Algorithm, 209
T
T cell, 121
interaction, 131
migration, 127, 131, 135
priming, 121, 131
dynamics, 142
T
H
1, 90
T
H
2, 90
TCR, 4, 9, 16, 48, 77, 172
agonist heteroclitic, 57
avidity, 48, 58, 84
degeneracy, 47
self-MHC restriction, 77
sub-optimal agonist, 57
TCR triggering
MHC-limited, 49
probability, 51
proofreading, 52
serial triggering, 52
TCR-limited, 49
TCR–pMHC binding, 27
TCR-CD3 complex, 77
telomere length, 147
thymus, 2, 77, 85
tolerance, 4, 12, 16–19
TREC, 145, 149
Tregs, 92, 306
two-photon microscopy, 13, 123, 137, 351
V
V-region, 242
variable region, 241
velocity of cells, 123
viral dynamics, 368
viral infection, 384, 385